$Hims & Hers Health (HIMS.US)$ dropped 11% after the Food and Drug Administration announced shortages of Eli Lilly's obesity and diabetes drugs Zepbound and Mounjaro have ended.
The company sells direct-to-consumer generic prescription medicines, including weight-loss drugs, and with Lilly's shortages, had taken advantage by creating copycat treatments.
Investors will keep their eyes on the upcoming Hims & Hers Health earnings report. Prior to Thursday's news, shares had increased 33.17% in the last month.